Patrys Ltd. engages in the commercialisation of the group’s proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The firm is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The 3E10 antibody has several unusual biological properties not typically seen in antibodies, such as cancer targeting, blood-brain barrier, cell penetrating and inhibit deoxyribonucleic acid (DNA) damage repair. The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The company also uses the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.
Patrys (ASX: PAB)
- Home
- Patrys (ASX: PAB)
Here are the latest articles on Patrys (ASX: PAB)
Preclinical data indicates Patrys’s therapeutic safely reduces inflammation in autoimmune disease
April 9, 2024
Melbourne-based therapeutic antibody development company Patrys (ASX: PAB) unveiled positive findings from preclinical studies using PAT-DX1 and PAT-DX3 in animal anti-neutrophil cytoplasmic antibody (ANCA) vasculitis models. Dr Kim O’Sullivan from Monash University presented the findings during the plenary session at the 21st International Vasculitis Workshop in Barcelona. He said, “Both PAT-DX1 and PAT-DX3 are able
Recent Articles
